GLPwatch
[Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
Vnitr Lek · 2016
Last updated 2026-05-28A large study called the LEADER trial found that people with type 2 diabetes and very high heart disease risk who took the drug liraglutide had better outcomes than those who did not. The trial specifically looked at how the drug affected heart-related health over time.
AI summary of the abstract below.
| Journal | Vnitr Lek, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
UNLABELLED: The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity-mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk.
KEY WORDS: cardiovascular risk - LEADER - liraglutid - type 2 diabetes mellitus.
Verbatim abstract via PubMed 27627086 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.